Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

IOVANCE BIOTHERAPEUTICS, INC.

(IOVA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/08/2021 06/09/2021 06/10/2021 06/11/2021 06/14/2021 Date
20.59(c) 20.64(c) 23.14(c) 23.45(c) 23.87(c) Last
3 945 096 3 010 053 6 579 891 6 388 263 3 074 742 Volume
+2.03% +0.24% +12.11% +1.34% +1.79% Change
More quotes
Financials (USD)
Sales 2021 - - -
Net income 2021 -306 M - -
Net cash position 2021 405 M - -
P/E ratio 2021 -11,6x
Yield 2021 -
Sales 2022 3,89 M - -
Net income 2022 -336 M - -
Net cash position 2022 152 M - -
P/E ratio 2022 -10,8x
Yield 2022 -
Capitalization 3 649 M 3 649 M -
EV / Sales 2021 -
EV / Sales 2022 899x
Nbr of Employees 241
Free-Float 93,7%
More Financials
Company
Iovance Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cell therapies as novel cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company has developed a shorter manufacturing process for Tumor infiltrating lymphocyte (TIL) therapy known as Generation 2... 
Sector
Biotechnology & Medical Research
Calendar
06/17 | 02:00pmPresentation
More about the company
Ratings of Iovance Biotherapeutics, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
C-
More Ratings
All news about IOVANCE BIOTHERAPEUTICS, INC.
06/14IOVANCE BIOTHERAPEUTICS, INC.  : Change in Directors or Principal Officers, Subm..
AQ
06/10SECTOR UPDATE : Health Care Stocks Helping Push Broader Markets Higher
MT
06/10IOVANCE BIOTHERAPEUTICS  : Shares Rally 11% After Upgrade From JMP Securities
MT
06/10SECTOR UPDATE : Health Care Stocks Leading Broader Thursday Rise for Equities
MT
06/10Today on Wall Street: Prices rise faster than expected in May
06/10ANALYST RECOMMENDATIONS : Ally Financial, Delta Air Lines, IAG, ServiceNow, Unit..
06/10IOVANCE BIOTHERAPEUTICS  : JMP Securities Upgrades Iovance Biotherapeutics to Ma..
MT
06/07SECTOR UPDATE : Health Care Stocks Gain Premarket Monday
MT
06/07IOVANCE BIOTHERAPEUTICS  : Announces Clinical Data for Lifileucel in Combination..
AQ
06/07IOVANCE BIOTHERAPEUTICS  : Says Follow-Up Study Data Show Durability, Depth of R..
MT
06/06Iovance Biotherapeutics Announces 33-Month Follow Up Data for Lifileucel in A..
GL
06/04IOVANCE BIOTHERAPEUTICS  : Reports Clinical Data On Potential Treatment For Adva..
MT
06/04Iovance Biotherapeutics Announces Clinical Data for Lifileucel in Combination..
GL
06/03ALPINE IMMUNE SCIENCES  : Appoints Chief Medical Officer
MT
06/01Iovance Biotherapeutics to Present at Upcoming Conferences
GL
More news
News in other languages on IOVANCE BIOTHERAPEUTICS, INC.
2020EN DIRECT DES MARCHES : Thales, Danone, Peugeot, Europcar, Ingenico, Disney, ..
2020STOCK MARKET PARIS : Rester sur le marché ou le quitter, telle est la question
2020EN DIRECT DES MARCHES : Renault, Peugeot, Casino, Vivendi, Bourbon, Gaumont, ..
2020STOCK MARKET PARIS : L'accord commercial Chine / Etats-Unis se profile
More news
Analyst Recommendations on IOVANCE BIOTHERAPEUTICS, INC.
More recommendations
Chart IOVANCE BIOTHERAPEUTICS, INC.
Duration : Period :
Iovance Biotherapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IOVANCE BIOTHERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 14
Average target price 36,50 $
Last Close Price 23,87 $
Spread / Highest target 114%
Spread / Average Target 52,9%
Spread / Lowest Target -24,6%
EPS Revisions
Managers and Directors
NameTitle
Maria Fardis President, Chief Executive Officer & Director
Jean-Marc Bellemin CFO & Principal Accounting Officer
Iain David Dukes Chairman
Friedrich Graf Finckenstein Chief Medical Officer
Igor P. Bilinsky Chief Operating Officer
Sector and Competitors
1st jan.Capitalization (M$)
IOVANCE BIOTHERAPEUTICS, INC.-48.56%3 584
EXACT SCIENCES CORPORATION-8.00%20 910
GUARDANT HEALTH, INC.-6.16%12 230
BGI GENOMICS CO., LTD.-7.00%7 659
INVITAE CORPORATION-25.33%6 239
ADAPTIVE BIOTECHNOLOGIES CORPORATION-34.45%5 438